Navigation Links
Global Market Study on Dermatophytic Onychomycosis Therapeutics (DOT): North America Expected to Account for Maximum Market Share by 2021, Due to Increasing Prevalence of Fungal Toe Nail Infections

LONDON, Feb. 25, 2016 /PRNewswire/ -- Dermatophytic onychomycosis is a fungal nail infection caused by dermatophytes. Dermatophytic onychomycosis is also known as tinea unguium. It is called the dermatophytic invasion of the nail plate. It is the most common nail infection and constitutes more than half of all nail disease cases. This condition mostly affects toenails. The overall prevalence rate of dermatophytic onychomycosis is around 10% in the general population. The disease can lead to severe pain and can impede work and social activities.

This report covers the global dermatophytic onychomycosis therapeutics market performance in terms of revenue contribution. The report includes key trends, drivers, restraints, and opportunities influencing the growth of the global dermatophytic onychomycosis therapeutics market. Impact analysis of key growth drivers and restraints, based on the weighted average model, are included to better equip clients with crystal clear decision-making insights.

The global dermatophytic onychomycosis therapeutics market is mainly driven by factors such as increasing the prevalence of dermatophytic onychomycosis, rising aging population, increasing consumer inclination towards maintaining aesthetic appearance of nails, and increasing per capita healthcare expenditure. Potential side effects of therapeutic products, availability of alternative treatments, and lack of awareness in emerging regions such as APEJ and MEA are expected to hinder the growth of the dermatophytic onychomycosis therapeutics market.

On the basis of products, dermatophytic onychomycosis therapeutics market is segmented into tablet and nail paint. Both the segments, tablet and nail paint are further sub-segmented into prescription and over-the-counter products. By distribution channel, dermatophytic onychomycosis therapeutics market is segmented into hospitals, clinics, independent pharmacies, mail order pharmacies, and drug stores.

By product, revenue from the tablet segment is projected to rise at the highest CAGR of 5.2% during the forecast period. The nail paint segment is expected to dominate the market, accounting for a maximum share of the overall market by 2021. The nail paint segment revenue is projected to rise at a CAGR of 8.3% during the forecast period (2015–2021).

By treatment, the topical segment is estimated to dominate the dermatophytic onychomycosis therapeutics market, accounting for a maximum share of the overall market by 2015 end. Revenue from the topical segment is projected to increase at a CAGR of 8.3% during the forecast period.

In terms of value, North America dominated the market with over 43% market share in 2014, followed by Europe. In Asia Pacific, this market is projected to expand at the highest CAGR of 5.1% during the forecast period.

Key players of the global dermatophytic onychomycosis therapeutics market are Valeant Pharmaceuticals International Inc., Galderma S.A., Novartis AG, Pfizer Inc., Moberg Pharma AB, Johnson & Johnson Services, Inc., and Anacor Pharmaceuticals, Inc. Leading players operating in the market collaborate with healthcare solutions and services providers in order to advance operational efficiencies and provide improved patient care.

The dermatophytic onychomycosis therapeutics market is segmented as follows:

By Product:
Prescription (Rx.)
Nail Paint
Prescription (Rx.)
By Treatment:
By Distribution Channels:
Independent Pharmacies
Mail Order Pharmacies
Drug Stores
By Region:
North America
Rest of Europe
Asia pacific
Australia & New Zealand
Rest of Asia Pacific
Latin America
Rest of Latin America
GCC Nations
South Africa
Rest of MEA

Key features included in this report:
Drivers and restraints of the dermatophytic onychomycosis therapeutics market
Latest product innovations and key developments in the market
Analysis of business strategies of the top players
Dermatophytic onychomycosis therapeutics market estimates and forecasts
Download the full report:

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at
Tel: +44 208 816 85 48

SOURCE ReportBuyer
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
4. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. TRACE Releases 2012 Global Enforcement Report
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
(Date:11/11/2019)... ... November 11, 2019 , ... MAPS and ... implementation of joint projects for the benefit of biomedical professionals in the ... professionals to leverage their roles in the research, development, and commercialization activities ...
(Date:11/11/2019)... ... November 11, 2019 , ... ... drug class and have a major impact in the oncology field. While ... need to be overcome. Among these, defining valuable and adapted combination protocols, ...
(Date:11/11/2019)... (PRWEB) , ... November 10, 2019 , ... ... rebranding alongside a redesign of its website , which features over 600 ... from the brand's 35+ year commitment to providing high-quality health and wellness products, ...
Breaking Medicine Technology:
(Date:11/11/2019)... ... 11, 2019 , ... As Americans celebrate Veterans Day and honor the brave ... remember that they also deserve recognition and compassionate care when dealing with an advanced ... is demonstrating its commitment to providing specialized care for Veterans who are facing ...
(Date:11/11/2019)... ... November 11, 2019 , ... ... for improved foodborne illness prevention and urges increased adoption of compliance technology in ... series of vegetable products sold to select retailers in the United States and ...
(Date:11/9/2019)... ... 08, 2019 , ... Mount Sinai Medical-Legal Partnership (MSMLP), an organization formed to ... free special education law and advocacy assistance to families and patients in need. The ... the work of contributions of Blaine (“Fin”) Fogg, who was a member of the ...
(Date:11/7/2019)... ... 07, 2019 , ... , Entomol’s safe and effective, EPA-approved all-natural insect ... a 4 and a 7 hour formulations. , “Entomol helps people live healthier lives ... Virus and Encephalitis, without exposing them to the harmful chemicals found in other repellents,” ...
(Date:11/6/2019)... ... November 06, 2019 , ... SPH Analytics , ... today that 94% of the health insurance plans receiving the highest 4.5- to ... plans, use SPH solutions according to reports recently released by the ...
Breaking Medicine News(10 mins):